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Therapy for ST-Segment Elevation
Myocardial Infarction Patients Who Present
Late or Are Ineligible for Reperfusion Therapy
Marc Cohen, MD, Catalin Boiangiu, MD, Mateen Abidi, MD
Newark, New Jersey
Despite the wide contemporary availability of pharmacological and mechanical means of reperfusion, a very sig-
nificant proportion of ST-segment elevation myocardial infarction (STEMI) patients are still not offered any reper-
fusion therapy, and some of them are considered “ineligible for reperfusion.” Spontaneous reperfusion and con-
traindications to the use of fibrinolytics and/or mechanical reperfusion methods account only for a small part of
these clinical situations. The boundary between “timely” and “late” presentation in STEMI, the appropriateness of
percutaneous intervention in patients presenting late after onset of symptoms, and the impact of sex and age on the
eligibility and/or choice of reperfusion therapy continue to be challenged by the most recent published data. In the
current invasive-driven reperfusion era, if scientific evidence and clinical guidelines are applied diligently, the vast ma-
jority of eligible STEMI patients should receive reperfusion therapy. Pharmacological nonlytic therapy of patients with
STEMI, regardless of the choice of reperfusion strategy or the absence of it, is clearly defined by the current practice
guidelines. Available data suggest that for patients who do not receive any form of reperfusion, anticoagulation ther-
apy with low molecular weight heparin provides a clear additional mortality benefit versus placebo. Fondaparinux as
compared with usual care (unfractionated heparin infusion or placebo) significantly reduces the composite of death or
myocardial reinfarction without increasing severe bleeding or number of strokes. In the treatment of late-presenting
patients with STEMI (beyond the first 12 h after onset of symptoms), clinical evaluation and risk stratification repre-
sent the crucial elements helping in decision making between therapeutic interventions. (J Am Coll Cardiol 2010;
55:1895–906) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.087r
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whe most severe form of acute coronary syndrome (ACS)
fter sudden cardiac death is ST-segment elevation myocar-
ial infarction (STEMI). According to the NRMI-4
Fourth National Registry of Myocardial Infarction), 29%
f infarction patients experience a STEMI (1), whereas a
uropean survey, the EHS-ACS-II (Second Euro Heart
urvey on Acute Coronary Syndromes), reported that 47%
f ACS patients present with STEMI (2).
Prompt and complete coronary reperfusion using fibrino-
ysis or primary percutaneous coronary intervention (PCI) is
he goal in STEMI, to reduce infarct size, adverse out-
omes, and mortality. Current guidelines advocate at-
empting reperfusion therapy for all STEMI patients
resenting within 12 h of symptom onset (3–5), and a
ecent analysis from the GRACE (Global Registry of
cute Coronary Events) shows that primary PCI is
rom the Division of Cardiology, Newark Beth Israel Medical Center, Newark, New
ersey. Dr. Cohen receives research and grant support from Sanofi-Aventis and
ristol-Myers Squibb, and is on the Speakers’ Bureau for Sanofi-Aventis, Bristol-
yers Squibb, and Schering-Plough.8
Manuscript received September 14, 2009; revised manuscript received November
8, 2009, accepted November 19, 2009.apidly becoming the preferred approach (6). However, a
ignificant proportion of STEMI patients are not offered
ny reperfusion therapy, and a small fraction of STEMI
atients are considered “ineligible for reperfusion.” In
his review, we will describe the burden of “STEMI with
o reperfusion therapy” and its causes, and review the
ata on antithrombotic and nonantithrombotic therapies
work-reducing and others) used in “no-reperfusion ther-
py” patients.
TEMI With No-Reperfusion Therapy
agnitude of the Problem
ndertreatment. In the era preceding the widespread use
f primary PCI, the German MITRA (Maximal Individual
herapy in Acute Myocardial Infarction) registry reported
hat no-reperfusion therapy was offered to 42.2% of patients
ith STEMI presenting within 48 h from symptom onset
7), whereas the French ACS registry from year 2000 reported
hat only 53% of STEMI patients presenting within 5 h of
ymptoms received reperfusion (8). In the EHS study, only
6% of STEMI patients received reperfusion therapy (35%
ith fibrinolytic agents, 21% with primary PCI) (9). Among
,305 patients with STEMI in the ACOS (Acute Coronary
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Nonreperfusion Therapies in STEMI May 4, 2010:1895–906Syndrome) registry, 28.3% did not
receive any form of reperfusion
(10). Between 2001 and 2002, in
the TETAMI (Treatment With
Enoxapam and Tirofiban in Acute
Myocardial Infarction) random-
ized trial and registry, 28% of pa-
tients presenting within 12 h from
onset of symptoms did not receive
reperfusion therapy (11). Unfortu-
nately, in the largest study to date
of patients with STEMI (12), only
half of the patients presenting
within 24 h and not treated with
mechanical reperfusion received fi-
brinolytic drugs. More recently,
some progress has been made. In
2006, 33% of the GRACE pa-
tients presenting within 12 h of
STEMI received no reperfusion
(Fig. 1) (6). In the NRMI registry,
the proportion of patients with
STEMI eligible for but not receiv-
ing any form of reperfusion ther-
apy slowly decreased from 1992,
but remained as high as 28.1% in
2006 (Fig. 2) (13). A similar pat-
ern was also seen in the more recent OASIS-6 (Sixth
rganization to Assess Strategies in Acute Ischemic Syn-
romes) trial (23.7% of patients not receiving reperfusion) (14).
What are the clinical outcomes of patients encountering
missed opportunities” for reperfusion? Most clinical trials
xclude these patients from their analyses. The few studies
ocusing on this topic demonstrate that the lack of reper-
usion therapy translates into worse outcomes. In the
ETAMI registry, 30-day mortality was only 4.4% in
atients who received reperfusion therapy, but 12% in
atients who did not receive it. Similarly, the triple end
oint of death, myocardial reinfarction, or recurrent angina
ccurred in only 11% of patients receiving reperfusion
ompared with 19.1% of patients who did not (Fig. 3). In
he ACOS registry, in-hospital mortality was 14% among
atients not receiving reperfusion and only 6.3% among
atients receiving reperfusion (10).
ariables Associated With No-Reperfusion Therapy
hy do so many patients presenting with STEMI within
2 h from onset of symptoms not receive any reperfusion
herapy? Spontaneous reperfusion and contraindications to
he use of fibrinolytics and/or mechanical reperfusion ac-
ount for a part of these clinical situations. In reality, these
ntities represent only a small fraction of the untreated pa-
ients. Another important association with no-reperfusion
herapy is represented by patients who present between 12 and
4 h or later after the debut of symptoms. By the time many
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
ACS  acute coronary
syndrome
ASA  acetylsalicylic acid
CI  confidence interval
LMWH  low molecular
weight heparin
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
RRR  relative risk
reduction
SR  spontaneous
reperfusion
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
UFH  unfractionated
heparinf these patients present to the hospital, their symptoms fave diminished, and many are hemodynamically and elec-
rically stable. The current STEMI guidelines do not
ecommend attempting mechanical or pharmacological
eperfusion in such “late” and stable patients. Figure 4
ummarizes the various clinical scenarios that can occur in
he setting of STEMI and the available therapeutic options.
atients presenting <12 h from onset of symptoms.
PONTANEOUS REPERFUSION. Spontaneous reperfusion (SR)
s a well-recognized scenario in STEMI, but its incidence
aries widely (4% to 57%) in different reports (15–17). In a
tudy of 710 STEMI patients eligible for reperfusion (15),
R (defined as 70% resolution of the cumulative ST-
egment elevation compared with the initial electrocardio-
ram, and 70% reduction in pain) was observed in 155
22%). The outcomes of patients with SR were better than
hose of patients without SR. On multivariate analysis, SR
as significantly associated with a lower incidence of the
omposite of 30-day mortality, congestive heart failure, and
ecurrent ACS. In a pre-specified subgroup analysis of the
PEX-AMI (Assessment of Pexelizumab in Acute Myo-
ardial Infarction) trial (16), SR defined as angiographic
IMI (Thrombolysis In Myocardial Infarction) flow grade
in the culprit vessel before PCI (first contrast injection),
ccurred in 11.5% of patients, and more commonly in
ondiabetic patients. Nondiabetic patients with SR showed
ignificant improvement in 90-day composite outcome of
eath, shock, or congestive heart failure versus without SR
4.0% vs. 8.9%, p  0.001). A systematic analysis of the
ccurrence and prognostic implications of SR using electro-
ardiographic and angiographic assessments was done in a
ubstudy of the ASSENT-4 (Assessment of the Safety and
fficacy of a New Treatment Strategy for Acute Myocardial
nfarction-4) PCI trial in 585 patients with STEMI ran-
omized into the primary PCI arm (17). The SR assessed by
70% cumulative ST-segment elevation resolution or by
IMI flow grade 3 in the infarct-related artery before PCI
s comparable (14.9% vs. 14.7%). However, only electrocar-
iographic SR was associated with a lower mortality,
hereas no such differences were evident in patients with
ngiographic SR versus no SR. This finding supports the
oncept that resolution of ST-segment elevation reflects
oth the recanalization of the culprit epicardial vessel and a
etter microvascular flow at the cellular level (18).
ONTRAINDICATIONS. Absolute and relative contraindica-
ions for fibrinolysis are clearly defined in the current
TEMI clinical guidelines and are mostly related to the risk
f intracerebral bleeding (3–5). The true incidence of these
ontraindications is rarely reported in clinical studies, but it
s probably very low. In the TETAMI randomized trial,
nly 1.4% of eligible patients did not receive fibrinolytic
herapy because of absolute contraindications, and 2.6%
ecause of relative contraindications (19). Primary PCI
arely has contraindications, except for the fear of bleeding
rom the adjunctive antithrombotic therapy (20).
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May 4, 2010:1895–906 Nonreperfusion Therapies in STEMIactors related to no-reperfusion therapy. An over-
helming majority of “eligible, but not receiving reper-
usion therapy” patients do not have SR or contraindica-
ions. In a 2002 GRACE analysis (21), 4 factors were
ound to be strongly related (odds ratio [OR]: 2.0) to
ailure to provide or receive reperfusion therapy in
TEMI: age 75 years, prior congestive heart failure,
rior myocardial infarction (MI), or prior coronary artery
ypass surgery. Other variables associated with not offer-
ng reperfusion were female sex, diabetes, and delayed
Figure 1 Use of Reperfusion Therapy From 1999 to 2006
The percentage of patients who received no reperfusion (open circles) decreased
the use of primary percutaneous coronary intervention (PCI) (solid circles), from 1
from 41% to 16% (Cochran-Armitage test for linear trend, *p  0.0001). Reproduc
Figure 2 Trends in Type of Reperfusion Therapy Among Patient
The National Registry of Myocardial Infarction registry data demonstrate that the in
lels a steady increase in the percentage of patients who are offered reperfusion th
myocardial infarction did not receive any reperfusion intervention (dash-dot line). S
Dashed line  fibrinolytic therapy; solid line  either. Reproduced with permissionresentation (6,21). Multivariate analysis of the com-
ined TETAMI randomized trial and registry patients,
evealed that delayed presentation (12 h), age 75
ears, systolic pressure 100 mm Hg, and geographic
egion were significant independent predictors of not
eceiving reperfusion therapy (22).
GE. Elderly patients (65 years of age) constitute one-half
f the hospital admissions for STEMI and account for as
any as 80% of STEMI deaths (23). Only 9% have absolute
om 40% in 1999 to 33% in 2006. During this interval, a continuous increase in
44%, was accompanied by a steady decline in the use of fibrinolysis (squares),
h permission from Eagle et al. (6).
ible for Reperfusion From 1990 to 2006
ed use of primary percutaneous coronary intervention (pPCI) (dotted line) paral-
; but even in 2006, approximately 30% of the patients with ST-segment elevation
004, pPCI is the most prevalent method of reperfusion in these patients.
Gibson et al. (13).only fr
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Nonreperfusion Therapies in STEMI May 4, 2010:1895–906ontraindications to fibrinolytic therapy (24). Nevertheless,
he MITRA registry identified advanced age at presentation
70 years) as 1 of the determinants of no-reperfusion
herapy in STEMI (7). As mentioned in the preceding text,
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Figure 3 Clinical Event Rates at 30 Days, by
Reperfusion Status in the TETAMI Registry and Trial
The absence of reperfusion therapy translates into significantly worse clinical
outcomes, as illustrated by the triple end point of death (orange areas), myo-
cardial reinfarction (blue areas), and recurrent angina (green areas). Mortality
almost triples among the TETAMI (Treatment With Enoxaparin and Tirofiban in
Acute Myocardial Infarction) registry patients who did not receive reperfusion.
Reproduced with permission from Cohen et al. (11).
Figure 4 Spectrum of Clinical Scenarios and Therapeutic Optio
PCI  percutaneous coronary intervention; STEMI  ST-segment elevation myocarhe GRACE revealed that patients 75 years of age were
ess likely to receive reperfusion therapy (OR: 2.63, p 
.0001, for younger vs. older than 75 years of age receiving
eperfusion). Similarly, the TETAMI trial and registry
ound an OR of 0.425 for receiving reperfusion in STEMI
atients 75 years of age (11).
In many STEMI trials, patients 75 years of age are
utrightly excluded from enrollment. Even in trials without
ge restriction, there are fewer elderly patients compared to
eal-life age distribution of STEMI. A recent scientific
tatement on this topic reveals that in the VIGOUR
Virtual Coordinating Center for Global Collaborative Car-
iovascular Research) pool of trials (comprising 100,000
atients with STEMI), only 14% were elderly, compared
ith the 25% to 30% in the NRMI and GRACE registries.
lderly patients present more often atypically, after longer
elays, and with multiple comorbidities. Hence, they are
ften not considered for enrollment in clinical trials (25). To
heir credit, the ExTRACT–TIMI 25 (Enoxaparin and
hrombolysis Reperfusion for Acute Myocardial Infarction
reatment–Thrombolysis In Myocardial Infarction 25) in-
estigators (26) enrolled 20,506 patients in the largest study
o date of fibrinolysis in STEMI, and 2,532 (12.4%) were
75 years old. The patients received either streptokinase or
fibrin-specific lytic, and were randomly assigned to enox-
parin versus UFH. The trial demonstrated that, by adjust-
ng the dose of anticoagulation therapy, the incidence of
STEMI
arction.ns in
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May 4, 2010:1895–906 Nonreperfusion Therapies in STEMIajor bleeding (2.9% with UFH and 3.3% with enoxaparin)
nd specifically intracranial hemorrhage (1.7% with UFH
nd 1.6% with enoxaparin) could be significantly mini-
ized in elderly STEMI patients (26). That represents a
ignificant advance when compared with previous lytic
tudies: in the ASSENT-3 and ASSENT-3 PLUS trials
analysis of combined data), the use of enoxaparin was
ssociated with a rate of major bleeding of 5.2%, and of
ntracranial bleed of 6.7% among the patients 76 to 85
ears old (27). The ExTRACT–TIMI 25 study demon-
trated that fibrinolytic drugs can be safely used in the
lderly provided that the adjunctive anticoagulant therapy
s adjusted. In a study conducted with 483 patients with
TEMI ages 75 to 85 years in Japan, 55% were treated
ith fibrinolytic agents (with a 92% rate of success) and
5% were offered “conservative therapy.” The pharmaco-
ogical reperfusion strategy did not provide any clinical
enefit in this trial, and the rate of cerebral hemorrhage
as similar (28).
In the Senior PAMI (Primary Angioplasty and Throm-
olytic Therapy in Elderly Patients With Acute Myocardial
nfarction) trial (29), 481 patients70 years of age present-
ng with STEMI within 12 h of symptoms were randomly
ssigned to PCI versus fibrinolytic therapy. There was a
onsignificant 36% reduction in death or nonfatal stroke
11.3% PCI vs. 13% thrombolytic therapy, p  0.57), but a
ignificant 55% reduction in death, stroke, or reinfarction
avoring PCI (11.6% PCI vs. 18% thrombolytic therapy,
 0.05). No difference between reperfusion strategies was
een in the subgroup of patients80 years of age (n 131).
imilarly, the recent TRIANA (Tratamiento del Infarto
gudo de Miocardio en Ancianos) trial treated patients
75 years of age presenting with STEMI within 6 h with
brinolytic therapy or primary PCI. The TRIANA study
howed a significant advantage of primary PCI with regard
o the secondary end point of recurrent ischemia (0.8% vs.
.7%, p  0.001 when compared with fibrinolysis) (30).
here was a favorable trend toward reduction of the
omposite primary end point of death, reinfarction, or
isabling stroke at 30 days with primary PCI, 18.9% versus
5.4% with fibrinolysis (p  0.21). In a pooled analysis of
2 randomized trials of PCI versus fibrinolytic therapy, the
CAT-2 (Primary Coronary Angioplasty vs. Thrombolysis)
nvestigators found that the absolute mortality advantage of
CI over fibrinolysis increased with age from 1% at 65 years
o 6.9% at 85 years (31). The small number (n  56) of
atients75 years of age with cardiogenic shock enrolled in
he SHOCK (Should We Emergently Revascularize Oc-
luded Coronaries for Cardiogenic Shock) trial did not
enefit from revascularization, prompting the guidelines’
ecommendation for early revascularization only for patients
75 years of age. However, in the associated SHOCK
egistry, among patients 75 years of age, those who
nderwent early revascularization (n  44) had a 50%
ower mortality rate than those who did not (n  233
relative risk: 0.46, 95% confidence interval [CI]: 0.28 to t.75, p  0.002]) (32). Similarly, a trial of 88 very old
atients (85 years) with STEMI treated with primary PCI
escribed good short- and long-term outcomes and identi-
ed age 90 years, late presentation, failed PCI (8% of
atients), and Killip class III or IV (17%) as predictors of
ortality at long-term follow-up (33). All these findings
uggest that in the absence of life-threatening comorbidi-
ies, advanced age alone should not limit the use of
eperfusion therapy for eligible elderly patients with
TEMI.
EX. Several studies suggest that female sex is associated
ith underutilization of reperfusion therapy. The MITRA
egistry showed that only 48.6% of women presenting with
TEMI received any form of reperfusion (primarily throm-
olysis) compared with 62.5% of men (OR: 0.83, p 
.002), even among eligible patients. Women, on average,
ere 9 years older than men, had longer pre-hospital delays,
nd more comorbidities, which might have contributed to
ower utilization of reperfusion. The multivariate, age-
djusted analysis of the MITRA registry demonstrated no
ifference in the long-term mortality between sexes (7). In
he TETAMI randomized trial and registry, there was also
trend toward more men than women receiving reperfusion
herapy (47.3% vs. 38.2%) (11). However, female sex was
ot retained as a predictor for not receiving reperfusion
herapy after multivariate analysis (22). Similar to the
ITRA registry, women in the TETAMI study were
lder, had higher Killip class at presentation, and presented
ater after symptom onset. More recently, the CRACE
Chinese Registry of Acute Coronary Events) showed that
ewer females received reperfusion therapy compared with
ales (26.8% vs. 37.1%, p 0.013) (34). The percentage of
omen 75 years of age (19.4%) was significantly higher
han for men (12.1%, p  0.0001); hence, an age-related
ias may account for the underutilization of reperfusion
trategies.
These findings suggest that female sex by itself is prob-
bly not directly associated with underutilization of reper-
usion therapy, but rather the increased likelihood of
omen, as opposed to men, to present later after onset of
ymptoms, have more atypical symptoms, more advanced
ge, and more comorbidities accounts for their being less
ikely to receive reperfusion therapy.
UMBER OF COMORBIDITIES. Identification of cardiac or
oncardiac comorbidities in STEMI patients poses addi-
ional challenges to the physician considering reperfusion
herapy. In a Canadian study, 73.5% of patients diagnosed
ith STEMI and eligible for reperfusion therapy received it
70.8% fibrinolysis and 2.6% primary PCI) (35). The
djusted probability of receiving any reperfusion therapy fell
y 18% with each additional pre-existing condition (Fig. 5).
The AMI-Florence registry enrolled 740 patients pre-
enting with STEMI within 12 h from the onset of
ymptoms. Only 63.5% of patients received reperfusion
herapy (91.5% primary PCI) (36). Similar to the Canadian
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Nonreperfusion Therapies in STEMI May 4, 2010:1895–906tudy, the proportion of patients receiving reperfusion
rogressively decreased with increasing chronic comorbid-
ty, from 78.8% in the lowest tertile to 41.9% in the highest.
t the same time, 1-year mortality was significantly reduced
y the use of reperfusion in the highest tertile of chronic
omorbidities (approximately 53% reduction) (Fig. 6).
hese examples illustrate the treatment-risk paradox ap-
lied to eligible STEMI patients: systematic underutiliza-
ion of reperfusion therapy in sicker patients limits the
pportunity of delivering the best treatment to the patients
ho will most benefit from it.
ATE PRESENTATION, >12 H FROM ONSET OF SYMPTOMS. The
mpact of the duration of symptoms on the decision to use a
eperfusion-based strategy in STEMI has undergone extensive
esearch. The most important element influencing outcomes in
atients with STEMI is the time from symptom onset to
eperfusion. The current guidelines strongly recommend reper-
usion therapy for patients presenting within 12 h of symp-
oms. This time limit derives primarily from the early reper-
usion trials using fibrinolytics, where the efficacy of
hrombolytic therapy (the mortality benefit), demonstrated an
mportant time-dependency. The GISSI (Gruppo Italiano per
o Studio della Streptochinasi nell’ Infarto Miocardico) trial
emonstrated that the reduction in mortality with streptoki-
ase decreased dramatically from 51% in patients treated
ithin 1 h of symptoms onset, to only 20% if thrombolysis was
erformed between 3 and 6 h from the onset of symptoms
37); and the LATE (Late Assessment of Thrombolytic
fficacy) study (38) showed no benefit for thrombolytic ther-
py in STEMI if administered 12 to 24 h after the symptoms.
The impact of “later” arrival to hospital, even within 12 h,
as described by an NRMI analysis: 77% of patients arriving
ithin 1 h received some form of reperfusion therapy, versus
Figure 5 Adjusted Probability of Reperfusion Therapy According
The number of pre-existing conditions represents the cumulative sum of all cardiac an
patient (diamonds), 65-year-old patient (squares), and 80-year-old patient (triangles).
socioeconomic status, ethnicity, hospital type, rural-urban status, and hospital arrival
existing conditions. Reproduced with permission from Parker et al. (35).nly 46% for patients presenting 11 to 12 h from onset of rymptoms. Patients with longer delays between symptom onset
nd presentation also had longer door-to-balloon time (99 vs. 123
in) and door-to-needle time (33 vs. 47 min) (39). Incremental
elays to mechanical reperfusion within the initial 12 h from the
nset of symptoms also adversely impacts survival and myocardial
ecovery after primary PCI (Fig. 7) (40).
A few studies prospectively investigated the benefit of
echanical reperfusion beyond 12 h. The “open artery
ypothesis” postulates that late mechanical recanalization
fter STEMI may prevent infarct expansion, electrical
nstability, and enhance collateral blood supply to other
erritories. In the OAT (Occluded Artery Trial), 2,166
table patients with an occluded infarct-related artery iden-
ified 3 to 28 days after STEMI were randomly assigned to
CI or conservative therapy (41). At the 4-year follow-up,
here were no differences between the groups in either the
ate of the primary composite end point of death, reinfarc-
ion, or New York Heart Association functional class IV
eart failure (17.2% vs. 15.6%, p  0.18) or mortality (9.1%
s. 9.4%). Of note, 90% of the patients in the OAT who had
stress test before randomization had absent or only mild
schemia. Thus, the lack of benefit observed in utilizing PCI
eyond 72 h from the index event in STEMI may be
onfined to patients without significant residual ischemia.
In contrast, the SWISSI-II (Swiss Interventional Study
n Silent Ischemia Type II) study (42), performed in the
re-stenting era, supports the idea that for patients with
ecent STEMI in whom exercise stress imaging revealed
ilent ischemia, balloon angioplasty reduces the long-term
ates of cardiac death, nonfatal MI, or symptom-driven
evascularization, and improves functional capacity and left
entricular ejection fraction at 4 and 10 years. Thus,
ignificant residual ischemia might still be present even in
he absence of chest pain, frequently interpreted as a
ge and Number of Pre-Existing Conditions
ardiac comorbid conditions and is stratified according to the typical 50-year-old
obability of reperfusion therapy (95% confidence interval) is adjusted for age, sex,
p  0.001 for the effects of age; p  0.001 for the effect of the number of pre-to A
d nonc
The pr
times.eflection of no active ischemia.
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onreperfusion therapeutic options for patients presenting
ate or considered ineligible for reperfusion therapy.
hile the current American College of Cardiology/
merican Heart Association and the European Society of
Figure 6
12-Month Cumulative Kaplan-Meier
Survival Curves by Coronary Reperfusion
Therapy Status and Chronic CS Category
Compared to a conservative approach, reperfusion therapy was not associated
with a significant reduction in 12-month mortality in the group of patients with
the least comorbidities (comorbidity score [CS]-1 [A], receiving reperfusion in
71.2% of cases). Even though used in a significantly lower percentage of
patients in the groups with more comorbidities (CS-2 [B] 51.1%, and CS-3 [C]
32.1%), reperfusion therapy was associated with a progressively larger and sig-
nificant reduction in 12-month mortality in these groups. Reproduced with per-
mission from Balzi et al. (36).ardiology guidelines for the management of all patientsith STEMI (3–5) recommend treatment with aspirin,
hienopyridines, UFH or low molecular weight heparin
LMWH), beta-blockers, angiotensin-converting enzyme
nhibitors (ACEIs), and statins, unless otherwise contrain-
icated, there are currently limited published data specifi-
ally addressing the efficacy of these interventions in pa-
ients with STEMI who present late or are ineligible for
eperfusion.
ntithrombotic therapy with platelet inhibitors. ORAL
GENTS, ACETYLSALICYLIC ACID. Platelet inhibition is the
ornerstone of antithrombotic treatment in STEMI and has
een shown to reduce mortality, with or without concom-
tant reperfusion therapy. The ISIS-2 (Second International
tudy of Infarct Survival) showed that aspirin alone in
atients with acute MI conferred an absolute risk benefit in
5-day mortality of 2.4% (relative risk reduction [RRR]
3%) compared with no antithrombotic therapy (43). This
as comparable to the benefit seen with streptokinase (Fig. 8).
he current guidelines for the treatment of STEMI in
atients with normal platelet counts suggest that acetylsal-
cylic acid (ASA) therapy is associated with an RRR in
ortality rate of 20% to 25% regardless of whether patients
Figure 7 Time Dependence of Myocardial Salvage
Time dependence of myocardial salvage according to time-to-treatment interval
in patients with ST-segment elevation myocardial infarction (STEMI) treated by
percutaneous coronary intervention (PCI [green bars]) or thrombolysis (blue
bars). (A) Myocardial salvage expressed as percentage of the left ventricle
(LV). (B) Myocardial salvage expressed as proportion of the initial area at
risk salvaged by reperfusion therapy. Reproduced with permission from
Schomig et al. (40).
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Nonreperfusion Therapies in STEMI May 4, 2010:1895–906re receiving reperfusion therapies (3–5). True aspirin hy-
ersensitivity is the only exception. A dramatic insight into
he role of ASA therapy is provided by cancer patients who
resent with ACS and thrombocytopenia, for whom ASA is
ften withheld because of fear of bleeding. In an observa-
ional study (44), the cancer patients diagnosed with ACS
nd having thrombocytopenia who did not receive ASA had
7-day survival rate of only 6% compared with 90% for
atients who received ASA (p  0.0001). Patients with a
latelet count 100 000 cells/l who did not receive ASA
ad a 7-day survival rate of 45%, compared with 88% in
atients who received ASA (p 0.01). Use of ASA was not
ssociated with more severe bleeding.
HIENOPYRIDINES. Clopidogrel is useful as a substitute for
spirin for patients with aspirin hypersensitivity (3–5), and
s recommended for patients with STEMI undergoing
eperfusion with either primary angioplasty or fibrinolysis.
What about the STEMI patients not receiving reper-
usion therapies? The ACOS registry (45) studied the
mpact of clopidogrel in addition to aspirin on 1-year
linical outcomes of survivors of STEMI treated with or
ithout reperfusion, and showed a reduction in major
dverse cardiac and cerebrovascular events (death, non-
atal reinfarction, and nonfatal stroke) with added clopi-
Figure 8 Mortality From Vascular Causes
to 35 days in ISIS-2 Trial
Assignment to 1 month of treatment with aspirin produced a significant reduc-
tion of about one-fifth in mortality (p  0.001), comparable to the use of strep-
tokinase alone in this study. The effects of aspirin on overall mortality are
similar whether or not patients receive fibrinolytic therapy or heparin. Repro-
duced with permission from the ISIS-2 (Second International Study of Infarct
Survival) Collaborative Group (43).ogrel in all subgroups of patients (Fig. 9). The absoluteortality benefit was greatest (8%) for the group of
atients without early reperfusion therapy, who had the
ighest 1-year mortality (18%), but after multivariate
nalysis remained significant only in patients receiving
eperfusion.
The COMMIT (Clopidogrel and Metoprolol in Myo-
ardial Infarction Trial) evaluated aspirin plus clopidogrel
or 4 weeks versus aspirin alone in 45,852 STEMI
atients presenting within 24 h of STEMI (mean 10 h,
4% 6 h) (12); 43% of patients received no-reperfusion
herapy. Compared with aspirin alone, dual-therapy re-
ipients had significantly lower 30-day incidence of the
omposite end point of death, reinfarction, or stroke
9.2% vs. 10.1%, p  0.002), and of death (7.5% vs. 8.1%,
 0.03). Subgroup analysis showed similar reductions
f the primary end point with clopidogrel irrespective of
he use of fibrinolytic therapy (11% reduction with
brinolytic therapy vs. 7% without).
arenteral platelet inhibitors. GLYCOPROTEIN IIb/IIIa
ECEPTOR BLOCKERS. The role of glycoprotein IIb/IIIa
nhibitors in restoring perfusion was investigated either in
ombination with thrombolytics or as an adjunct to primary
ngioplasty. There are no data to support the use of
ntravenous glycoprotein IIb/IIIa inhibitors alone as an
ntiplatelet agent in the absence of reperfusion in STEMI.
he TETAMI randomized trial (19) demonstrated that
ddition of tirofiban to either UFH or LMWH did not
rovide additional benefit regardless of the use of
eperfusion.
ntithrombotic therapy with parenteral anticoagulants.
FH. Randomized data supporting the use of UFH in
atients with acute MI, including STEMI, come from an
arlier era in which patients were not routinely treated with
Figure 9 Incidence of MACCE After
1 Year Among Survivors of STEMI
Incidence of major adverse cardiac and cerebrovascular events (MACCE [death,
nonfatal reinfarction, nonfatal stroke]) after 1 year in survivors of ST-segment
elevation myocardial infarction (STEMI) treated with aspirin (green bars) or
aspirin and clopidogrel (blue bars) at discharge. The reduction in mortality with
clopidogrel was approximately 5% in both patients with fibrinolysis and primary
percutaneous coronary intervention (PCI) and approximately 8% in patients
without early reperfusion therapy. After multivariate analysis, the reduction of
mortality remained significant only for patients receiving reperfusion. Acute Cor-
onary Syndromes registry; reproduced with permission from Zeymer et al. (45).
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May 4, 2010:1895–906 Nonreperfusion Therapies in STEMIspirin and/or fibrinolytic therapy. The systematic overviews
y Collins et al. (46,47) from all randomized trials (almost
3,000 patients in 26 trials) of early anticoagulation therapy
or patients with suspected acute MI assessed the effects of
dding UFH to aspirin or the effect of UFH alone on death
nd other major clinical events. In the trials with no
oncomitant aspirin, roughly 14% were given fibrinolytic
herapy, whereas in trials with concomitant aspirin (almost
8,000 patients in 6 trials), 93% received fibrinolytic ther-
py. In the absence of aspirin, heparin therapy reduced
ortality (11.4% vs. 14.9% in control group, RRR: 25 
%, 95% CI: 10% to 38%, p 0.002), reduced stroke (1.1%
s. 2.1%, p  0.01) and pulmonary embolism (2% vs. 3.9%,
 0.001). There was a significant increase in major bleeds
2.3% vs. 1.1%, p 0.01). In the presence of aspirin, adding
FH reduced mortality (8.6% vs. 9.1% in the aspirin-alone
roup, p  0.03), and reinfarction (3% vs. 3.3% for aspirin
lone, p  0.04), but there was a significant excess of major
leeds (1% vs. 0.7%, p  0.0001).
MWH. LMWH has been extensively evaluated in prospec-
ive randomized trials of STEMI patients including those
ho did not receive any reperfusion therapy. The TETAMI
rial (19) evaluated 1,224 STEMI patients who were not
ligible for reperfusion therapy. Enoxaparin subcutaneously
wice daily for 2 to 8 days was compared with intravenous
FH, with and without the glycoprotein IIb/IIIa receptor
ntagonist tirofiban, in a 2  2 factorial design. There were
o significant differences between the enoxaparin and UFH
roups in the combined incidence of death, reinfarction, or
ecurrent angina at 30 days, or in safety. Additional therapy
ith tirofiban was not beneficial.
In a pre-specified subgroup analysis of the CREATE
Clinical Trial of Metabolic Modulation in Acute Myocar-
ial Infarction Treatment Evaluation) (48), the LMWH
eviparin was assessed versus placebo in 3,325 of the 15,570
TEMI patients (21%) who did not receive any reperfusion
herapy. Reviparin twice daily for 7 days reduced the
omposite of death, myocardial reinfarction, and stroke at 7
ays versus placebo in these nonreperfused patients (OR:
.79, 95% CI: 0.65 to 0.95).
The OASIS-6 randomized trial evaluated the impact of
aily fondaparinux during hospital stay, compared with
tandard approaches to anticoagulant therapy in a broad
ange of patients with STEMI treated with primary PCI,
hrombolysis, or no-reperfusion therapy (14). In the sub-
roup of patients not receiving reperfusion therapy,
ondaparinux as compared with usual care (UFH infusion or
lacebo) significantly reduced the composite of death or
yocardial reinfarction without increasing severe bleedings
r strokes (49).
Compared with UFH, these trials suggest that, in
TEMI patients who present late or are ineligible for
eperfusion therapy, LMWHs given along with aspirin
rovide significant benefit, and their use in these patients is supported by both current European and North American
TEMI guidelines (3,4,50).
ARENTERAL DIRECT THROMBIN INHIBITORS. The
ERO (Hirulog and Early Reperfusion or Occlusion)-2
tudy (51) evaluated the role of direct thrombin inhibition as
n adjunctive therapy to thrombolytics in STEMI. Adjunc-
ive bivalirudin did not reduce mortality compared with
FH (10.8% vs. 10.9%), but was associated with a lower
ate of adjudicated myocardial reinfarction within 96 h
1.6% vs. 2.3%, p  0.005). There are no data available on
he role of direct thrombin inhibitors in STEMI with
o-reperfusion therapy.
ntithrombotic therapy with oral anticoagulants. The
ffect of anticoagulation therapy with warfarin on mortality
nd reinfarction after MI was studied by the Norwegian
ARIS (Warfarin-Aspirin Re-Infarction Study) (52) and
ARIS 2 (53) trials, which enrolled survivors of acute MI
STEMI and NSTEMI). In the WARIS, the majority of
atients did not receive any reperfusion therapy, and war-
arin use was associated with a 24% RRR in mortality, 34%
RR in nonfatal recurrent MI, and 55% RRR in cerebro-
ascular accidents compared with placebo. The absolute risk
f serious bleeding increased by 0.6% per year in the
arfarin-treated patients. Of note, 90% of the patients
andomly assigned to the warfarin arm received therapy
eginning at least 2 weeks after the index event. In the
ARIS 2 study, 46% of patients did not receive any
eperfusion therapy, and warfarin in combination with
spirin or given alone, was superior to aspirin alone in
educing the incidence of composite events after MI. The
otal number of events were 24.5% in the aspirin-alone
roup, 19.4% in the warfarin-alone group, and 17.4% in the
ombined-therapy group (mean international normalized
atio 2.0). In the similarly designed ASPECT-II (Aspirin
nd Coumadin After Acute Coronary Syndromes) trial (54),
he combination therapy with aspirin and warfarin (mean
nternational normalized ratio 2.4) provided a 50% RRR in
he combined end point of death, MI, or stroke compared
ith aspirin alone (RRR: 0.5, 95% CI: 0.27 to 0.92) up to
6 months after MI. As emerged from these trials, the
ombination of moderate intensity warfarin and a low dose
f aspirin was the most effective therapy for the prevention
f recurrent ischemic events after MI. The slightly higher
ates of major and minor bleed in both warfarin groups, as
ell as the need for frequent international normalized ratio
easurements and dose adjustments with this agent, have
imited the use of oral anticoagulants post-MI in the U.S.
onantithrombotic therapies: work-reducing therapies
nd others. BETA-BLOCKERS. There is substantial evidence
or the benefits of early beta-blockade in patients with
TEMI and no contraindications. Benefits have been dem-
nstrated for patients with and without concomitant fi-
rinolytic therapy and both early and late after STEMI. In
he ISIS-1 (First International Study of Infarct Survival)
tudy (55), patients with an acute MI treated with intrave-
n
t
o
t
v
M
t
I
A
t
i
b
S
m
m
M
t
n
h
8
(
l
r
t
s
l
fi
r
r
(
M
i
r
w
r
t
fi
r
S
N
(
u
t
s
b
S
S
n
o
c
t
m
S
C
V
c
d
m
r
t
F
w
r
(
w
s
S
p
h
S
c
c
I
a
r
m
A
d
y
r
S
r
i
f
a
t
m
u
r
w
v
(
d
b
a
e
a
f
d
c
a
r
t
s
1904 Cohen et al. JACC Vol. 55, No. 18, 2010
Nonreperfusion Therapies in STEMI May 4, 2010:1895–906ous atenolol demonstrated a 14% RRR in 7-day mor-
ality compared with controls, and reductions in the rates
f reinfarction, arrhythmia, and cardiac arrest. Despite
he evidence of benefit from beta-blockers, findings from
arious studies indicate their considerable underuse after
I, with only 20% to 50% of eligible patients receiving
hem (56).
NHIBITION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM.
number of large, randomized clinical trials have assessed
he role of ACEI early in the course of acute MI. All trials
n which ACEI were administered orally demonstrated a
enefit in mortality. The ISIS-4 (Fourth International
tudy of Infarct Survival) trial (57) studied the effects of
ononitrates, captopril, and intravenous magnesium on
ortality and morbidity in patients with suspected acute
I. Patients were randomly allocated to receive mononi-
rate or placebo, captopril or placebo, or intravenous mag-
esium versus no treatment. Of the 58,050 patients, 92%
ad confirmed MI and the median time to treatment was
h, 79% had STEMI, 70% received thrombolytic therapy
predominantly streptokinase), and 94% received antiplate-
et agents. The ISIS-4 study provided evidence that ACEIs
educe short-term and 1-year mortality in MI patients. In
he GISSI-3 trial (58), 19,000 patients with either ST-
egment elevation or depression were randomly assigned to
isinopril or to open control: 71% of the patients received
brinolytic treatment, 84% received aspirin, and only 3%
eceived other antiplatelet agents. There was a significant
eduction in 6-week mortality in patients receiving lisinopril
OR: 0.88, 95% CI: 0.79 to 0.99). The SMILE (Survival of
yocardial Infarction Long-term Evaluation) study (59)
nvolved 1,556 patients randomly assigned within 24 h to
eceive either placebo or zofenopril. The patient population
as restricted to those with anterior MI who had not
eceived fibrinolytic therapy. The early use of an ACEI in
his trial conferred a trend of reduction in mortality in the
rst 6 weeks (RRR: 25%, p 0.19). These data support the
ole of ACEI with or without reperfusion therapy in
TEMI.
ITRATES. Clinical trials such as ISIS-4 (57) and GISSI-3
58) have suggested only a modest benefit of nitrates when
sed acutely in STEMI. Nitrates are useful only for the
reatment of recurrent angina, and should not be used if the
ubsequent hypotension limits the administration of beta-
lockers or ACEI, which have more powerful benefits for
TEMI patients.
TATINS. The early use of statins in ACS (STEMI and
on-STEMI) reduces both short and long-term adverse
utcomes such as subsequent cardiovascular mortality, MI,
oronary revascularization, and stroke (3,4). Many ACS
rials do not specifically report the use of statins, and the
ore recent statin trials were conducted in the setting of
TEMI receiving reperfusion therapy. tonclusions
ery few patients with STEMI present with true or relative
ontraindications for reperfusion therapy. If scientific evi-
ence and clinical guidelines are applied diligently, the vast
ajority of STEMI patients should receive some form of
eperfusion therapy. The ESTIM (Evaluation of Therapeu-
ic Strategies for Myocardial Infarction) Midi-Pyrénées, a
rench multidisciplinary, prospective registry of patients
ith STEMI, demonstrated that it is possible to apply a
evascularization strategy in as many as 89.4% of patients
60). Recently published data from a single French center
ith a systematic reperfusion policy showed that a reperfu-
ion therapy can be implemented in as many as 96% of
TEMI patients admitted within 6 h of symptoms, and this
olicy was associated with a significant decrease of in-
ospital mortality (61).
For the treatment of late-presenting patients with
TEMI (beyond the first 12 h after onset of symptoms),
linical evaluation and risk stratification represent the cru-
ial elements guiding the choice of therapeutic intervention.
n the presence of hemodynamic or electrical instability,
nd/or if the patient continues to experience symptoms, a
eperfusion-based strategy using primary PCI is recom-
ended and endorsed by the current guidelines (3–5).
mong clinically stable, late-presenting patients, myocar-
ial viability assessment and functional testing can identify
et another subgroup that may benefit from late mechanical
eperfusion.
Pharmacological nonlytic therapy of patients with
TEMI is clearly defined by the current practice guidelines,
egardless of the reperfusion strategy or the absence of it. As
n patients who receive reperfusion therapy, the nonreper-
used patients derive the most benefit from an appropriate
ntithrombotic regimen. Early initiation of dual-antiplatelet
herapy with aspirin and a thienopyridine drastically reduces
ortality and subsequent cardiovascular events in this pop-
lation. Available data suggest that for patients who do not
eceive any form of reperfusion, anticoagulation therapy
ith LMWH provides a clear additional mortality benefit
ersus placebo. Fondaparinux as compared with usual care
UFH or placebo) significantly reduces the composite of
eath or myocardial reinfarction without increasing severe
leeding or number of strokes. Post-discharge chronic
nticoagulation therapy post-STEMI is currently re-
merging, and with the advent of novel, safer oral antico-
gulant agents (direct thrombin inhibitors or selective direct
actor Xa inhibitors) (62,63), new clinical studies may
emonstrate additional reductions in long-term cardiovas-
ular events. Among work-reducing therapies, renin-
ngiotensin-aldosterone system modulation with ACEIs
educes early and late mortality in STEMI patients even in
he absence of a reperfusion strategy. Chronic ubiquitous
tatin use after ACS provides a significant additional reduc-
ion in subsequent cardiovascular events.
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